低毒性微小環境におけるがん幹細胞を標的とし,腫瘍発生を防ぐための小分子戦略

Ji Hyeon Kim¹, Peter Verwilst¹, Miae Won¹

¹Department of Chemistry, Korea University, Seoul 02841, Korea.

Journal of the American Chemical Society

|August 10, 2021

まとめ

AzCDFという新しい小分子は低酸素環境における乳がん幹細胞 (BCSCs) を標的にしますこのアプローチは腫瘍の成長と転移を効果的に抑制し侵襲的な乳がんに対する新しい戦略を提供します

科学分野:

腫瘍学
分子生物学
薬物の発見

背景:

乳がんは癌幹細胞 (CSC) によって引き起こされる異質な疾患です.
乳がん幹細胞 (BCSC) は転移と再発に関与しています.
BCSCは低毒性ニッチで繁栄し化学療法に耐性を与えます

研究の目的:

BCSCの標的治療のための新しい小分子構造,AzCDFを開発する.
低酸素腫瘍環境におけるAzCDFの有効性を評価する.
AzCDFが腫瘍形成を防ぐ可能性を調査する.

主な方法:

低酸素トリガーであるアセタゾラミド (Az) とクルクミン (CDF) を含むAzCDFの設計
AzCDFがBCSCに及ぼす影響を評価するインビトロおよびインビボ試験
CSCの移動,腫瘍の成長,および腫瘍発生に対するAzCDFの影響の評価.

主要な成果:

AzCDFは低毒性条件下でBCSCを選択的に標的とする.
AzCDFはCSCの移動を減らし,腫瘍の成長を遅らせる.
AzCDFは腫瘍発生率を in vivoで低下させる能力を示しています.

結論:

AzCDFは,選択的なBCSCターゲティングのための低酸素性の分子プラットフォームを表します.
この研究は,動物モデルで腫瘍形成を防ぐことが示された最初のCSC標的小分子を示しています.
AzCDFは耐性乳がんに対する有望な治療戦略です.

さらに関連する動画

07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.6K

07:03

Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples

Published on: October 2, 2020

4.7K

関連する概念動画

02:57

Targeted Cancer Therapies

8.0K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

8.0K

02:40

Cancer Stem Cells and Tumor Maintenance

5.1K

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

5.1K

02:53

Adaptive Mechanisms in Cancer Cells

6.0K

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

6.0K

02:49

Cancer Therapies

8.8K

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

8.8K

01:15

Drugs that Stabilize Microtubules

2.2K

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...